August 5th 2025, 7:00pm
TAMs may help predict response to PD-1 inhibitors in metastatic clear cell kidney cancer, Dr. Berkay Simsek reported at the 2025 Kidney Cancer Summit.
August 5th 2025, 1:00pm
Dr. Jacob A. Sands shares how antibody-drug conjugates, such as Datroway, work to selectively target and destroy tumor cells among those with lung cancer.
August 5th 2025, 12:05pm
Panelists discuss City of Hope’s multidisciplinary approach, highlighting pharmacists providing medication guidance, social workers offering emotional support, and palliative care specialists managing symptoms, while consultants like cardiologists and infectious disease experts address specific health issues to ensure coordinated, personalized care; complementary therapies such as acupuncture and mindfulness help manage side effects like neuropathy, and support groups foster community and resilience among patients and caregivers throughout their myeloma journey.
August 5th 2025, 12:00pm
Panelists share that despite initial emotional challenges, multiple myeloma treatment with targeted combination therapies was generally well tolerated, with manageable side effects—especially after adjusting dexamethasone—and strong healthcare team support enabling patients to maintain quality of life and continue regular activities throughout therapy.
August 4th 2025, 8:02pm
Jake Messier uses TikTok to raise awareness about male breast cancer, calling out stigma and isolation that delay diagnosis and harm treatment outcomes.
August 2nd 2025, 6:00pm
CURE spoke with an expert to learn what patients need to know about immunotherapy-induced diabetes.
August 1st 2025, 8:00pm
Robotic and video-assisted thoracic surgery reduces recovery time for those with lung cancer, allowing some to leave the hospital the day after surgery.
August 1st 2025, 1:00pm
Dr. Jacob Sands discusses the significance of the FDA approval of Datroway for the treatment of patients with locally advanced or metastatic EGFR+ NSCLC.
July 31st 2025, 8:00pm
Dr. Janet Kukreja explains one urinary diversion option available to patients undergoing bladder removal.
July 31st 2025, 3:00pm
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
How to Individually Tailor Myelofibrosis Treatment Options
A Day in the Life of a Breast Cancer Survivor
Jakafi for Myelofibrosis Associated With Skin Cancer, Shingles Risk
FDA Grants Designation to Investigational Drug for Head and Neck Cancer